At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 62 enrolled
Drug / intervention
ELX-02 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating ELX-02 and Placebo for Genetic Disease and Nonsense Mutation. Completed, enrolled 62 participants across 1 site.
Detailed Summary
Phase 1 Multiple Ascending Dose Study in Normal Healthy Volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenetic Disease, Nonsense Mutation
CountriesBelgium
CollaboratorsSGS Life Sciences, a division of SGS Belgium NV
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedOct 2017
Primary CompletionJun 2019
Study CompletionJul 2019
TodayJul 2026
First PostedOct 13, 2017
Enrollment StartOct 11, 2017
Primary CompletionJun 17, 2019
Study CompletionJul 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.7 years ago
Interventions
ELX-02drug
ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
Placebodrug
Placebo